SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
scPharmaceuticals Inc. (SCPH) , forward earnings yield 11.72%. PEG 0.13 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (100/100, Pass) — PEG ≤ 1.0 — Peter Lynch undervalued (0.13); analyst target implies upside (+129.3%).
- Forward P/E 8.5
- PEG Ratio 0.13 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Analyst consensus target $13.00 (+129.3% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 45/100 with 2/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
✗
HEALTH
33/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — SCPH
Valuation Multiples
P/E (TTM)0.0
Forward P/E8.5
PEG Ratio0.13
Forward PEG0.13
P/B Ratio0.00
P/S Ratio6.95
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-1.91
Forward EPS (Est.)$0.67
Book Value / Share$0.00
Revenue / Share$0.82
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Forward Earnings Yield11.72%
Dividend Yield0.00%
Analyst Target$13.00 (+129.3%)
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2015 |
$-0.94 |
$0.00 |
$-10.52M |
- |
| 2016 |
$-2.18 |
$0.00 |
$-24.38M |
- |
| 2017 |
$-8.04 |
$0.00 |
$-23.82M |
- |
| 2018 |
$-1.59 |
$0.00 |
$-29.44M |
- |
| 2019 |
$-1.85 |
$0.00 |
$-34.42M |
- |
| 2020 |
$-1.40 |
$0.00 |
$-34.39M |
- |
| 2021 |
$-1.11 |
$0.00 |
$-30.49M |
- |
| 2022 |
$-1.32 |
$0.00 |
$-37.52M |
- |
| 2023 |
$-1.42 |
$13.59M |
$-54.81M |
-403.2% |
| 2024 |
$-1.91 |
$36.33M |
$-85.15M |
-234.4% |
